**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 64368

**Manuscript Type:** REVIEW

**Recent trends in stem cell-based therapies and applications of artificial intelligence in regenerative medicine**

Mukherjee S *et al*. Recent trends in stem cell-based therapies

Sayali Mukherjee, Garima Yadav, Rajnish Kumar

**Sayali Mukherjee, Garima Yadav, Rajnish Kumar,** Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, Uttar Pradesh, India

**Author contributions:** Mukherjee S and Kumar R conceived of this manuscript; Yadav G and Mukherjee S performed the literature review and initial data collection; Mukherjee S, Yadav G and Kumar R wrote the manuscript; Kumar R and Mukherjee S edited and prepared the manuscript for submission.

**Corresponding author: Rajnish Kumar, BPharm, MTech, PhD, Assistant Professor,** Amity Institute of Biotechnology, Amity University Uttar Pradesh, Near Malhaur Railways Station, Lucknow 226028, Uttar Pradesh, India. rkumar2@lko.amity.edu

**Received:** February 16, 2021

**Revised:** March 22, 2021

**Accepted:** May 20, 2021

**Published online:** June 26, 2021

**Abstract**

Stem cells are undifferentiated cells that can self-renew and differentiate into diverse types of mature and functional cells while maintaining their original identity. This profound potential of stem cells has been thoroughly investigated for its significance in regenerative medicine and has laid the foundation for cell-based therapies.Regenerative medicine is rapidly progressing in healthcare with the prospect of repair and restoration of specific organs or tissue injuries or chronic disease conditions where the body’s regenerative process is not sufficient to heal. In this review, the recent advances in stem cell-based therapies in regenerative medicine are discussed, emphasizing mesenchymal stem cell-based therapies as these cells have been extensively studied for clinical use. Recent applications of artificial intelligence algorithms in stem cell-based therapies, their limitation, and future prospects are highlighted.

**Key Words:** Artificial intelligence; Machine learning; Mesenchymal stem cells; Regenerative medicine; Stem cells; Therapy

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

Mukherjee S, Yadav G, Kumar R. Recent trends in stem cell-based therapies and applications of artificial intelligence in regenerative medicine. *World J Stem Cells* 2021; 13(6): 521-541 URL: https://www.wjgnet.com/1948-0210/full/v13/i6/521.htm DOI: <https://dx.doi.org/10.4252/wjsc.v13.i6.521>

**Core Tip:** This article reviews some important types of stem cells in clinical treatment including embryonic stem cells, induced pluripotent stem cells, induced tissue-specific stem cells, and adult stem cells. Furthermore, the article focuses on the clinical treatment of mesenchymal stem cells and the application of artificial intelligence in induced pluripotent stem cells, their limitations, and future prospects.

**INTRODUCTION**

Stem cells hold great potential in regenerative medicine as these cells are endorsed with indefinite self-renewal characteristics and can be differentiated into any cells of the body. These cells express specific markers and are karyotypically normal. Based on the differentiation potential, stem cells can be categorized as totipotent, pluripotent, multipotent, or unipotent[1,2]. Totipotent cells are those that can form the entire organism. In animals, only the zygote is totipotent, and therefore, cannot be used for therapeutic purposes. The pluripotent embryonic stem cells (ESCs) are isolated from the inner cell mass (ICM) of the embryo's blastocyst. These pluripotent cells can differentiate into all cells, including germ cells but not the entire organism. The multipotent cells can generate a definite group of cells, *e.g.*, hematopoietic stem cells (HSCs) or mesenchymal stem cells (MSCs). The unipotent stem cells have restricted potential and can differentiate into a single cell type, *e.g.*, a neuronal stem cell. Stem cells have been classified according to the origin into ESCs and tissue-derived stem cells[3,4]. The tissue-derived stem cells may be adult stem cells (ASCs) isolated either from bone marrow, peripheral blood[5], adipose tissue[6], dental pulp[7], skeletal muscle[8], skin[9], neural tissue[10], liver[11], heart[12], pancreas[13] or intestine[14]. ASCs have reduced potency compared to ESCs. They are still preferred over ESCs for regenerative medicine because of ethical issues associated with ESCs. The fetal stem cells can be isolated from either fetal tissue like blood, spleen, liver, kidney, or extraembryonic sources like an amnion, amniotic fluid, umbilical cord, Wharton's jelly, and placenta. The HSCs and MSCs isolated from fetal tissues or extraembryonic sources have greater potential than their adult counterparts. Therefore, these cells are considered a "half-way house" between the ESCs and ASCs in terms of plasticity[15,16]. Induced pluripotent stem cells (iPSCs) are produced by reprogramming differentiated cells into an undifferentiated state[17]. These reprogrammed stem cells are artificially produced cells with properties of ESCs. Induced tissue-specific stem (iTS) cells have recently been produced by incomplete reprogramming and tissue-specific selection[18,19].

Cell therapy applies the biochemical and biophysical properties of stem cells to generate healthy tissues and repair damaged organs, preventing them from further damage[20]. The bone marrow serves as a source of stem cells from where HSCs, neural stem cells, and MSCs can be derived for therapeutic purposes[21]. These cells (termed adult cells) are non-pluripotent, limiting them to proliferate in only those types of tissues from which they have been isolated. Further advancement in stem cell therapy happened with identifying pluripotency of ESCs in 1998[22]. As the generation of ESCs involves the exploitation of embryos, this raised major ethical issues and limited the scope of stem cell-based therapies yet again until the creation of iPSCs in 2007[23-25]. Stem cell therapy holds the solid potential for combat transplantation-related issues such as graft rejection or tissue insufficiency and opens the door for precision medicines. Figure 1 depicts regenerative strategies, MSC differentiation, iPSCs, and the role of artificial intelligence (AI) in regenerative medicines.

The non-pluripotent nature of available ASCs has restrained the scope of cell therapy in regenerative medicine. The ESCs have their share of ethical and fewer availability issues. These limitations called for an advancement in cell therapy and led to the creation of iPSCs. The genetic reprogramming of ASCs has imparted them with ESC-like functional similarity and pluripotency, generating iPSCs[26,27]. iPSCs have gained popularity in multiple facets of cell-based therapies by serving as an unlimited source of any cell type of interest[28]. It has enabled the employment of iPSCs as novel human disease models[29,30], which have been applied to drug discovery as well as the fields of precision medicine and regenerative medicine[31]. Several preclinical studies in animal models have established MSC suitability for regenerative medicine[32]. Although several clinical trials have been carried out with stem cells to treat genetic disorders, autoimmune diseases, or degenerative disorders, several challenges and limitations are encountered in human clinical translation, which are being addressed to improve the regenerative potential of these cells.

**CURRENT TRENDS IN THE THERAPEUTIC USE OF STEM CELLS**

***ESCs***

ESCs exhibit pluripotency and differentiate into the three germ layers: ectoderm, mesoderm, and endoderm. These cells are derived from the ICM layer of the embryo's blastocyst. Mouse ESC was first derived in 1981 by Evans and Kaufman[33] in the United Kingdom and Martin[34] in the United States from the ICM of the blastocyst (d2.5). Human ESCs (hESCs) were derived by Thomson and colleagues isolated from preimplantation blastocysts[22]. hESCs have been an excellent source of pluripotent cells for therapeutic use[35]. Derivation of pluripotent ESCs from the blastocyst’s ICM layer is usually done by a standardized immunosurgery technique[36]. The ESCs are isolated and seeded on feeder layers in culture plates. The cells may be characterized for pluripotency markers by immunostaining using specific antibodies to octamer-binding transcription factor ¾ (Oct3/4), stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, TRA-1-60, and TRA-1-81 or by assessing alkaline phosphatase activity. ESCs are karyotypically normal and possess a high telomerase activity[37,38]. However, there are severe concerns in using ESC in regenerative medicine despite being a promising candidate. Severe ethical concerns prevail in using human embryos for the isolation of hESCs[39]. Different legal guidelines are governing ESC research in various countries. In the United States, the destruction of human embryos for any form of research is banned. According to the guidelines, hESC-lines derived before August 9, 2001 can be used for research. The development of hESC therapies is restricted, and most research studies are focused on animals[40]. In the United Kingdom, research using hESCs derived from discarded embryos in in vitro fertilization clinics is allowed; however, hESC research is prohibited in Italy[41-43].

It is also essential to analyze the safety issues associated with ESCs in regenerative medicine. The ESCs can differentiate into any cell type of the body. However, when these undifferentiated cells are implanted *in vivo*, this plasticity poses the risk of developing teratomas and tumors[44-47]. The alternative method is to differentiate the undifferentiated ESCs *in vitro* into a specific cell type along a lineage and then transplant the differentiated cell *in vivo*. hESC-derived cardiomyocytes, when transplanted in mice, did not result in teratoma[48]. However, in certain instances, the transplanted progenitor cells continue to proliferate, as, for example, nestin+ dopaminergic neurons derived from hESCs continue to proliferate in the striatum[49]. The screening of the undifferentiated cells by specific markers and their subsequent purification before transplantation may solve the problem.

There are some reported methods to overcome the risk of tumorigenesis, such that ESCs can be used for regenerative therapies[50]. One of the recent findings involves cluster of differentiation 133 (CD133) (prominin 1), a transmembrane protein generally expressed on cancer stem cells is highly expressed on hESCs. CD133-deficient knock-out hESC line retained the capacity to differentiate into the three embryonic germ layers *in vivo*. Still, the proliferating potential is reduced and results in reduced teratoma formation[51]. Therefore, CD133 may be used to sort ESCs for transplantation[52].

Despite the safety issues, hESC-derived progenitor cells are still considered promising candidates in regenerative medicine under controlled conditions[53]. The first approval of the hESC trial for spinal cord injury was received in 2009, in which hESC-derived oligodendrocytes progenitor cells were used[54]. The hESC-based clinical trials have been performed for the treatment of macular degeneration with some positive results in follow-up studies[55-58], diabetes mellitus[59], and ischemic heart disease[60]. One clinical trial has been approved for Type 1 diabetes produced by the company ViaCyte (ClinicalTrials.gov Identifier: NCT03163511, NCT02239354)[61]. These pancreatic progenitor cells are produced from human pluripotent stem cells *in vitro* and differentiate into beta cells after transplantation in an immune isolation device *in vivo*[62]. Clinical trials for Parkinson’s disease with hESCs are being conducted in Australia (NCT02452723) and China (NCT03119636)[63].

***iPSCs***

iPSCs were first successfully generated by Takahashi and Yamanaka[64] in 2006 by inserting the reprogramming factors known as “Yamanaka factors,” Oct4/3, Sox2, Klf4, and c-Myc in mouse fibroblast cells. Initially, Yamanaka and his group (Okita *et al*[65]) started transducing mouse fibroblasts with a recombinant retrovirus carrying 24 genes responsible for maintaining the ESC characteristics. The mouse fibroblasts were selected by antibiotic-resistant gene cassette under the promoter, Fbx15, which is active only in the ESCs. The number of genes was narrowed down to ten and finally to four genes, Oct3/4, c-Myc, Sox2, and Klf4. The first generation induced pluripotent cells selected by Fbx15 possessed unlimited self-renewal and differentiation capacity, produced embryoid bodies and fetal chimeras but failed to produce adult chimeras. However, the DNA methylation pattern, post-translational modifications, and epigenetic changes revealed that the generated iPSCs were intermediate between fibroblasts and ESCs. Yamanaka and his group further generated second-generation iPSCs using the selection for Nanog instead of Fbx15 selection. The second-generation iPSCs showed greater ES cell-like characteristics, DNA methylation pattern, and germline competence[65]. However, 20% of the chimeric mice developed cancer as two of the genes, c-Myc, and Klf4, are oncogenic. Human-induced pluripotent cells were generated from somatic cells in 2007 by two independent groups simultaneously by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog and Lin28[66]. The latter group has shown that reprogramming of human somatic cells is possible even when the reprogramming factors are not integrated into the genome. The use of non-integrated episomal vectors makes these cells more suitable for clinical use[67]. iPSCs have also been derived from peripheral blood mononuclear cells[68]. Adenovirus has also been used vector for the delivery of reprogramming factors.

However, virus-mediated delivery systems sometimes threaten iPSCs' clinical use due to insertional mutagenesis, mainly caused by cMyc[69-71]. RNA, proteins, and small molecules enhance iPSCs' efficiency and safety. Reprogramming of somatic cells by mRNA or microRNA became very successful and effective[72-75]. It has been reported that activation of the innate immune system enhances the efficiency of induced pluripotent cells by mRNA transfection[76]. Insertion of recombinant proteins such as Oct 4, sex-determining region Y-box 2 (Sox2), Kruppel-like factor 4 (Klf4), and cMyc can be used to reprogram somatic cells to induce pluripotent cells[77-79]. The protein-based approach has been used to generate dopaminergic neurons from iPSCs to treat Parkinson’s disease in rats[80].

The iPSCs have potential similar to that of ESCs, and additionally overcome the ethical concerns associated with ESC research and clinical use. The iPSCs have gained much attention in recent years because of their advancement in regenerative medicine, organoid formation, and scope for personalized therapies. The first human clinical trial with iPSCs was done for macular degeneration in which retinal pigmented epithelial cells generated from autologous iPSCs were transplanted into a patient[81]. There have been several *in vitro*[82,83] and *in vivo* preclinical studies investigating the safety and efficacy of iPSCs[84-87]. A human clinical trial was recently conducted to treat Parkinson’s disease in Kyoto, Japan, by transplanting dopaminergic neurons generated from iPSCs. The clinical-grade iPSCs are produced from cells taken from healthy volunteers[88]. Autologous iPSC-derived dopaminergic neurons transplanted in a patient with Parkinson’s disease retained the function until 2 years without any adverse effect[89]. Autologous iPSCs are more advantageous to avoid immunological rejection, but the development of autologous iPSC is time-consuming and costly.

The iPSC technology has enormous potential in regenerative medicine. However, more interventional studies[90] must be conducted to address the challenges of routine clinical applications of these cells *e.g.*, genomic instability[91], carcinogenicity[92], immunological rejection[93]. Humanized mouse models, *e.g.*, a mouse with human immune cells, may be developed in the future to investigate the immunogenicity of human pluripotent stem cells[94].

***iTS***

iTS are produced by incomplete reprogramming of somatic cells by transient overexpression of reprogramming factors by plasmids and performing a tissue-specific selection. These cells have the potential to self-renew but also express tissue-specific markers. iTS have been produced from mouse pancreatic cells, which can self-renewal and express pancreatic tissue-specific transcription factor, Pdx1[13]. These generated iTS can differentiate into insulin-producing cells more efficiently than ESCs or iPSCs and, probably, can be utilized to treat diabetes. iTS with neural stem cell-like characteristics have also been reported[95-98]. Teratoma formation is not reported when iTS are transplanted in nude mice. In this respect, iTS are advantageous over the ESCs or iPSCs in terms of clinical applications due to the risk of tumorigenicity associated with the use of pluripotent stem cells. These cells are “incompletely reprogrammed” cells and have different methylation patterns than ESCs or iPSCs. The iTS retain the donor tissue’s epigenetic memory and can be explored as a potential candidate for cell replacement therapy.

***Fetal stem cells and ASCs***

Fetal stem cells are collected from aborted fetal tissues and extraembryonic structures like amniotic fluid, umbilical cord, Wharton’s jelly, and placenta[99]. The fetal stem cells are multipotent HSCs or MSCs. HSCs collected from fetal bone marrow or umbilical cord express CD34 and CD45 Like adult HSCs but show greater proliferating capacity, low immunogenicity, and lower risk of graft *vs* host disease (GvHD) compared to adult HSCs. Fetal MSCs can be isolated from fetal blood, bone marrow, liver, lung, or pancreas. These cells have more differentiation capacity than the adult MSCs. Fetal MSCs have active telomerase and express low levels of human leukocyte antigen (HLA) I and lack intracellular HLA II[100]. First trimester fetal MSCs express baseline levels of pluripotent stem cell markers such as Oct4, Nanog, Rex1 SSEA3, SSEA4, Tra-1-60, and Tra-1-81. Umbilical cord blood MSCs are easy to harvest and can be stored under controlled conditions for longer periods for future clinical use[101]. Although the ethical concerns associated with fetal stem cells are minimal, there are several reports on the adverse effects of fetal stem cells *in vitro* in animals and humans[102]. Thromboembolism has been reported in patients who received transplantation of umbilical cord blood MSCs[103]. Placental-derived MSCs express higher levels of tissue factor[104,105], which aggravates the thrombotic events in patients infused with these MSCs for treatment of Crohn’s disease[106]. The ASCs are less prevalent and undifferentiated cells present in various adult tissues with a primary role of repair and maintenance of residing tissues.

***HSCs***

ASCs are derived from different tissues and have limited potency compared to the ESCs or iPSCs. ASCs are named depending on the tissue of origin, *e.g.*, HSCs, pancreatic stem cells, corneal stem cells, *etc.* HSCs were the first multipotent ASCs isolated from the bone marrow[107]. HSC transplantation is used as therapy for several malignant and non-malignant disorders and autoimmune diseases. These cells are also used for the recovery of patients undergoing chemotherapy and radiotherapy[108]. The allogeneic transplantation requires matching HLA, Class I, and Class II between donor and recipient[109]; however, there are risks of GvHD[110]. The emergence of more modern and less toxic methods of treatments replaces HSC transplantation in hematologic malignancies. Recent reports suggest that risks of bloodstream infections caused by Gram-negative bacteria are associated with allogeneic hematopoietic transplantation[111,112]. Hemorrhagic cystitis is another complication that has been reported in patients post-HSC transplantation[113].

***MSCs***

Cell-based therapy using MSCs is currently an essential domain of research. MSCs may be isolated from various sources, including bone marrow, adipose tissues, dental pulp, peripheral blood, synovium, and extraembryonic sources, as described earlier. These cells are plastic adherent and multipotential and can differentiate into bones, cartilage, fat tissues, muscles, and tendons[114]. The International Society for Cellular Therapy defined MSCs as plastic adherent cells expressing CD73, CD105, CD90 (≥ 90%), and not expressing hematopoietic markers CD34, CD45, CD14, CD19, and HLA-DR (≤ 2%) and have the potential of multilineage differentiation to osteogenic, adipogenic and chondrogenic lineage[115]. There is, however, no single marker to identify MSCs from various sources[116-118]. Figure 2 shows immune-modulatory characteristics and the ability of differentiation of MSCs.

The three primary characteristics of MSCs are: Differentiation into specific cell types and their incorporation into tissues that make it suitable for regenerative medicine; secretion of cytokines and exosomes that stimulate cell growth and proliferation and modulate inflammation; and direct contact with the host tissue and regulate effector function[119,120]. MSCs are therapeutically more successful due to the multipotentiality, immunomodulatory, anti-inflammatory, efficient homing capacity to injured sites, and minimum ethical issues[121-123]. However, there are disparities in MSC potency and pharmacological functionality, depending on tissue sources, cell handling, method of harvest, cultural expansion, dose, and route of delivery[124].

The most important sources of MSCs for clinical trials are bone marrow and adipose tissues[125]. Although MSCs isolated from the bone marrow have been extensively studied. However, there are several challenges in the clinical use of these cells. Cells collected from bone marrow are contaminated with HSCs, and a very small fraction (0.001%-0.01%) of MSCs are harvested from bone marrow. The cells isolated also show early signs of senescence during culture[126]. Although the collection of bone marrow aspirate is considered safe, certain complications and morbidity have been reported during collection from the sternum and posterior iliac crest[127]. Adipose tissue-derived stem cells are another potential source of MSCs by less invasive procedures[128]. Adipose tissue is abundant in the body and can be easily collected by liposuction, and the yield of stem cells is comparatively greater without any adverse effects. Adipose tissue-derived stem cells have more stability in the culture and have greater differentiation potential to osteocytes, chondrocytes, adipocytes, cardiomyocytes, and neurocytes[129]. Several studies have reported adipose tissue-derived MCSs' efficacy and safety for regenerative medicine[130,131]. The other sources include dental pulp, tendon, or from the perivascular fraction of any tissue[132].

MSCs have immunomodulatory properties and can reduce the inflammatory response. These cells can modulate the function of the innate and adaptive immune response. MSCs have very low levels of major histocompatibility complex and reduced expression of FasL (Fas Ligand) or costimulatory signals like B7, CD40, or CD40L[133]. MSCs secrete extracellular vesicles containing various growth factors and cytokines that suppress B lymphocyte and T lymphocyte function and maturation of dendritic cells while activating T regulatory cells. MSCs also secrete angiogenic, antiapoptotic, and antioxidative effects[134]. Table 1 summarizes the discovery time, sources, advantages, disadvantages, current clinical applications and prospects of various stem cells.

**TRENDS IN APPLICATIONS OF MSC-BASED THERAPIES IN REGENERATIVE MEDICINE**

MSCs have been utilized for preclinical and clinical studies for a wide range of diseases owing to multipotentiality, immunomodulation, and regeneration. The first clinical trials involved the infusion of MSCs post high dose chemotherapy and reversing GvHD, which is resistant to steroids[135]. To date, numerous clinical trials have been undertaken using MSCs for various diseases like myocardial infarction, Crohn’s disease, multiple sclerosis, diabetes, GvHD, amyotrophic lateral sclerosis, arthritis, neurodegenerative disorders, trauma, coronavirus disease 2019, and many more[136] (Table 2). According to recent reports, 10000 patients have undergone treatment with MSCs for different diseases, and 1094 clinical trials are registered at present in different phases[137]. Due to the relative ease of isolation and efficacy, the most prevalent source of MSCs for therapeutic purposes remains bone marrow, followed by the umbilical cord and then adipose tissue. Placental MSCs represent less than 2% of all clinical trials, and then MSCs from other sources are utilized[138].

**RECENT AI-BASED MODELS FOR STEM CELLS THERAPY**

The conventional approach of regenerative medicine and cell-based therapies faced multiple challenges related to the enormous amount of data analysis, rising quantity and complexity, standardization methods, manual errors, and extremely difficult data handling. This further complicates the process of conclusion derivation and decision-making practices without the risk of errors involved. The implementation of iPSCs in different experimental and therapeutic approaches requires identifying iPSC-derived cells, a thorough estimation of iPSC quality, and characterization of the cell type. Evaluation of colony morphology through a manual approach is a tedious and error-prone process, and it is not feasible for large-scale cultures. Various study groups have implemented different AI algorithms to install an automated approach for accurate segmentation and colony quality estimation to overcome this limitation.

AI raised major hopes in this aspect and became a synergistic approach that augments human expertise[153-155]. AI refers to an imitation of human intelligence that imparts to a machine the ability to interpret and learn from external data[156] and later use those learnings to anticipate and do self-amendment in similar or novel scenarios[157]. AI uses automated algorithms to solve problems and assist in tasks like data mining and analyzing enormous amounts of datasets, observe patterns and predict outcomes that would not be possible by human intelligence[158]. AI-based technologies potentially aid clinical decision support in real-time, resulting in improved precision medicine[159].

The two AI algorithms which are most widely adopted in the healthcare industry are machine learning (ML) and deep learning (DL) (Figure 3)[160,161]. ML refers to a data-based algorithm that allows the software to learn from first-hand information and become "intelligent" enough to perform predictive analysis and classification without being programmed for it[162]. The ML learning methods have been categorized into three types: supervised, unsupervised, and reinforcement learning. Supervised learning holds most of the ML tasks, and its training dataset consists of class labels. The label is a specific known outcome of interest, and the ML algorithm finds the best way to predict that outcome[163]. Unsupervised learning predicts the outcome without any prespecified labels and predicts the unknown patterns within the data. The supervised ML algorithms used in the field of medicine commonly include artificial neural network (ANN), support vector machine (SVM), naïve bayes, random forest (RF), k-Nearest Neighbors, decision tree (DT), and adaptive boosting (Adaboost), *etc.*[164]. Among these, ANN is the most widely used ML algorithm alongside SVM. ANN is a simulation of the human neuronal structure where neurons serve as the basic unit for communication and are arranged in sequential layers, with varying strength connections between layers. The input layer receives the training signal in pixel series or a speech series, relayed through the hidden layer where the data is analyzed. The concepts within the data are extracted to make the predictions and passed on to the output layer. The output layer further refines the data by performing classification/regression tasks[165]. DL's revolutionary concept emerged with an increased number of hidden layers, making it a more complex and, subsequently, even more, advanced concept of AI. DL techniques utilize these massive hidden neuronal units to automatically learn the complex relationship among the raw and noisy data, eliminating the tedious manual feature extraction required in ML algorithms[166]. Convolutional neural network (CNN) is a DL network robustly implemented in medical-imaging to perform image-classification and disease diagnosis tasks[167]. Figure 4 illustrates the general schema for AI-based prediction model development.

Joutsijoki *et al*[168] conducted a study focusing on an automated approach to identify iPSC colony images with 1608 × 1208 resolution by using ML classifiers- SVMs and k-NN. The authors also used scale-invariant feature transform descriptors in feature extraction. The k-NN classifier with Euclidean measure and equal weighting yielded the best result with an accuracy of 62.4%, which was a measured value compared to previous studies.

Kavitha *et al*[169] conducted a study to evaluate different automated texture features extracted from the segmented colony sections of iPSCs and use ML techniques to confirm their potential for characterization of colonies. They quantified 151 features obtained from the iPSCs images from phase-contrast microscope using moment-based, shape-based, spectral texture feature and statistical groups. A forward stepwise regression model was used to select the most relevant features for categorizing the colonies. Five ML classifiers- SVM, RF, MLP, Adaboost, and DT were used with 10-fold cross-validation to estimate the texture features within each texture-feature group and fused-feature groups to characterize diseased and healthy iPSC colonies. Based on one of their findings, SVM, RF, and Adaboost classifiers were concluded to exhibit superior performances compared to MLP and DT.

Several studies have reported the implementation of the DL algorithm through CNNs in iPSC studies. Kavitha *et al*[170], in their study, developed a vector-based CNN (V-CNN) using extracted features of the iPSC colony for finding out colony characteristics. They compared the V-CNN model with an SVM classifier using textural, morphological, and combined features. The study applied 5-fold cross-validation to examine the V-CNN performance. The precision, recall, and F-measure values were comparatively much higher than SVM (87%-93%). The V-CNN model was also subjected to determine the colony quality where the accuracy values on textural (91.0%), morphological (95.5%), and combined features (93.2%) bases were also found to be much higher than those of SVM values, which were 83.3%, 87.6%, and 83.4% respectively. In another study by Kusumoto *et al*[171], CNN's were utilized to identify iPSC-derived endothelial cells without immunostaining or lineage tracing. They obtained a dataset of 200 images from four experimental setups, of which 64 were applied for training alongside 160 for testing purposes. iPSC-derived endothelial cells' morphological descriptors (Phase-contrast images-based) were used to train the network. Its prediction validation was done by comparing with immunofluorescence staining for CD31, which is an endothelial cells marker. The method parameters were iteratively and automatically improved to obtain an error-free prediction. It was found that prediction accuracy was a function of the pixel size of the images and network depth in question. The k-fold cross validation also suggested that morphological features alone could be enough for optimizing CNNs, and they can deliver a high-value prediction. The next year, Waisman *et al*[172] used CNNs to separate pluripotent cells from initial differentiating cells. The authors used light microscopic images of PSCs to train the CNN model. Images of mouse-embryonic cells induced to epiblast-like cells were taken at different intervals after induction. The findings suggested that CNN can be trained to distinguish among differentiated and undifferentiated cells with an accuracy of 99%.

The well-established role of iPSCs in disease modeling and AI in therapeutics has also been exploited in several studies. Juhola *et al*[173] used iPSC-derived cardiomyocytes to study drug effects and their calcium transient signals with ML. Six iPSC-lines containing various catecholaminergic polymorphic ventricular tachycardia causing mutations were used to assess the drug-effect. The drug being studied was dantrolene after adrenaline stimulation by ML analysis of Ca2+ signals.

They identified the beats of transient signals with a previously proposed analytical algorithm[174], which recognizes signal abnormality depending upon whether the assessed cell signal has at least one abnormal transient peak-based on characteristics of a single peak. They computed 12 peak-variables for all identified signal-peaks. These data were used to classify the signals into various classes that correspond to those influenced by dantrolene or adrenaline. The algorithm's best classification accuracy was found to be nearly 79% suggesting a significant role of ML in the analysis of iPSC-cardiomyocytes drug effects.

In a similar study, Hwang *et al*[175] employed advanced ML techniques with an Analytical Algorithm to build an analytical pipeline for automatic evaluation of Ca2+ transient anomaly in cardiomyocytes. The pipeline was made up of peak detection, peak and signal abnormality assessment, and peak and signal variable detection. A peak-level SVM classifier was trained by using manual expertise. Two hundred cells were used as training data to train the SVM (cell-level), and other datasets of 54 cells were used to test the accuracy. The training and test accuracies were found to be 88% and 87%, respectively.

In a recent study, Nishino *et al*[176] developed a linear classification learning model to differentiate between iPSCs, ESCs, somatic cells, and embryonal carcinoma cells based on DNA methylation profiles. The accuracy of the ML model in identifying various cell types was found to be 94.23%. Furthermore, component analysis of the learned models identified the distinct epigenetic signatures of the iPSCs. Studies about recent AI-based stem cell therapies are summarized in Table 3.

Apart from the above-mentioned studies that demonstrate applications of AI in cell culture stages, sufficient evidences are available that AI could play a significant role in predicting the MSC’s therapeutic outcomes[177-179]. Precise therapeutic outcome prediction of the MSC therapy could provide vital information for clinicians to assist them in decision support and decide the optimized treatment strategies. AI algorithms could be applied to optimize the clinical trials of innovative stem cell therapies for various diseases by precise treatment-planning for patients, clinical outcomes prediction, and patient recruitment, thereby reducing the complexity of the study and overall costs[180]. Machine and human intelligence together could have an exponentially high impact on the continual progress of stem cell-based therapy.

**CONCLUSION**

***Research gaps and future prospect***

Regenerative medicines offer enormous potentials for better treatment of patients and quick recovery. However, there are certain drawbacks due to inefficient production, lengthy and complex processes, and human errors due to excessive human efforts. Understanding genetic components that influence the development of shape, size and orientation of an organ is extremely vital. Although the mechanism of most of the regenerative models is available with diagrams depicting the gene regulations, however, the stepwise dynamics to produce a particular shape of an organ are lacking. The AI-driven models and constructive algorithms could be a powerful solution for a deeper understanding of such mechanisms. These models could make the development of regenerative medicines automated and minimize human error factors.

The regenerative medicines' manufacturing has its own set of challenges, viz. efficient, cost-effective, large-scale production, lack of automation and quality control systems, and absence of closed and modular systems[181].

A vast number of datasets are published every year for experimental regenerative biology, but there is no international guideline for standard and high-quality datasets for regenerative medicines. Also, the tools for analyzing available datasets to get deeper insights and meaningful patterns are lacking. There have been some limited non-AI-based computational methods, platforms, and tools available to assist regenerative therapies. In an effort to derive such computational methods, Lobo and Levin developed a computational method to understand the physiological controls in planarian regeneration[182]. The exceptional ability of planaria to regenerate its body parts could be a potential model for leading regenerative medicine research. Another computational platform, KeyGene[183], can predict the tissue origin of various cell types. It could find out the equivalent stage of human PSC differentiation products along with the identification of stem cell derivatives. The KeyGene algorithm applies next-generation sequencing and microarray datasets and could be used to predict human adult tissue identity. This tool also helps monitor the cell-differentiation conditions and evaluate in-vitro cell-differentiation efficacy, thereby fetching improved protocol outcomes. CellNet[184] is among the recent computational tools that provide cell identity parameters, evaluate cell fate conversions, and rank suitable candidates for future interventions. However, it cannot differentiate between cell subtypes and cell heterogenicity, which remains a challenge to solve to date.

Nevertheless, AI-driven methods have emerged as an important component of stem cell research. Over the last decade, AI algorithms have advanced very rapidly, and along with enormous progress, methods to apply them have also enhanced subsequently. Many algorithms and tools can be expected in the recent future, which could efficiently assist stem cell-based regenerative medicines development, outcome prediction, and decision support to healthcare providers.

**REFERENCES**

1 **Bacakova L**, Zarubova J, Travnickova M, Musilkova J, Pajorova J, Slepicka P, Kasalkova NS, Svorcik V, Kolska Z, Motarjemi H, Molitor M. Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review. *Biotechnol Adv* 2018; **36**: 1111-1126 [PMID: 29563048 DOI: 10.1016/j.biotechadv.2018.03.011]

2 **Bissels U**, Diener Y, Eckardt D, Bosio A. Characterization and classification of stem cells. In: Steinhoff G, editor. Regenerative Medicine – From Protocol to Patient. Cham, Switzerland: Springer International Publishing, 2016: 1-25

3 **Ullah I**, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. *Biosci Rep* 2015; **35** [PMID: 25797907 DOI: 10.1042/BSR20150025]

4 **Noguchi H**, Saitoh I, Tsugata T, Kataoka H, Watanabe M, Noguchi Y. Induction of tissue-specific stem cells by reprogramming factors, and tissue-specific selection. *Cell Death Differ* 2015; **22**: 145-155 [PMID: 25190146 DOI: 10.1038/cdd.2014.132]

5 **Esposito MT**. Blood factory: which stem cells? *BMC Hematol* 2018; **18**: 10 [PMID: 29760931 DOI: 10.1186/s12878-018-0105-4]

6 **Zimmerlin L**, Donnenberg VS, Rubin JP, Donnenberg AD. Mesenchymal markers on human adipose stem/progenitor cells. *Cytometry A* 2013; **83**: 134-140 [PMID: 23184564 DOI: 10.1002/cyto.a.22227]

7 **Stanko P**, Altanerova U, Jakubechova J, Repiska V, Altaner C. Dental Mesenchymal Stem/Stromal Cells and Their Exosomes. *Stem Cells Int* 2018; **2018**: 8973613 [PMID: 29760738 DOI: 10.1155/2018/8973613]

8 **Hinken AC**, Billin AN. Isolation of Skeletal Muscle Stem Cells for Phenotypic Screens for Modulators of Proliferation. *Methods Mol Biol* 2018; **1787**: 77-86 [PMID: 29736711 DOI: 10.1007/978-1-4939-7847-2\_6]

9 **Ojeh N**, Pastar I, Tomic-Canic M, Stojadinovic O. Stem Cells in Skin Regeneration, Wound Healing, and Their Clinical Applications. *Int J Mol Sci* 2015; **16**: 25476-25501 [PMID: 26512657 DOI: 10.3390/ijms161025476]

10 **Zhang J**, Lu X, Feng G, Gu Z, Sun Y, Bao G, Xu G, Lu Y, Chen J, Xu L, Feng X, Cui Z. Chitosan scaffolds induce human dental pulp stem cells to neural differentiation: potential roles for spinal cord injury therapy. *Cell Tissue Res* 2016; **366**: 129-142 [PMID: 27147262 DOI: 10.1007/s00441-016-2402-1]

11 **Willemse J**, Lieshout R, van der Laan LJW, Verstegen MMA. From organoids to organs: Bioengineering liver grafts from hepatic stem cells and matrix. *Best Pract Res Clin Gastroenterol* 2017; **31**: 151-159 [PMID: 28624103 DOI: 10.1016/j.bpg.2017.03.003]

12 **Klopsch C**, Skorska A, Ludwig M, Gaebel R, Lemcke H, Kleiner G, Beyer M, Vollmar B, David R, Steinhoff G. Cardiac Mesenchymal Stem Cells Proliferate Early in the Ischemic Heart. *Eur Surg Res* 2017; **58**: 341-353 [PMID: 29073604 DOI: 10.1159/000480730]

13 **Saitoh I**, Sato M, Soda M, Inada E, Iwase Y, Murakami T, Ohshima H, Hayasaki H, Noguchi H. Tissue-Specific Stem Cells Obtained by Reprogramming of Non-Obese Diabetic (NOD) Mouse-Derived Pancreatic Cells Confer Insulin Production in Response to Glucose. *PLoS One* 2016; **11**: e0163580 [PMID: 27662374 DOI: 10.1371/journal.pone.0163580]

14 **Barisas DAG**, Stappenbeck TS. Intestinal Stem Cells Live Off the Fat of the Land. *Cell Stem Cell* 2018; **22**: 611-612 [PMID: 29727673 DOI: 10.1016/j.stem.2018.04.018]

15 **Abdulrazzak H**, Moschidou D, Jones G, Guillot PV. Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. *J R Soc Interface* 2010; **7 Suppl 6**: S689-S706 [PMID: 20739312 DOI: 10.1098/rsif.2010.0347.focus]

16 **Zakrzewski W**, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther* 2019; **10**: 68 [PMID: 30808416 DOI: 10.1186/s13287-019-1165-5]

17 **Takahashi J**. Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. *Prog Brain Res* 2017; **230**: 213-226 [PMID: 28552230 DOI: 10.1016/bs.pbr.2016.11.004]

18 **Noguchi H**, Miyagi-Shiohira C, Nakashima Y. Induced Tissue-Specific Stem Cells and Epigenetic Memory in Induced Pluripotent Stem Cells. *Int J Mol Sci* 2018; **19** [PMID: 29561778 DOI: 10.3390/ijms19040930]

19 **Miyagi-Shiohira C**, Nakashima Y, Kobayashi N, Saitoh I, Watanabe M, Noguchi H. Characterization of induced tissue-specific stem cells from pancreas by a synthetic self-replicative RNA. *Sci Rep* 2018; **8**: 12341 [PMID: 30120295 DOI: 10.1038/s41598-018-30784-0]

20 **Mahla RS**. Stem Cells Applications in Regenerative Medicine and Disease Therapeutics. *Int J Cell Biol* 2016; **2016**: 6940283 [PMID: 27516776 DOI: 10.1155/2016/6940283]

21 **Kumar R**, Sharma A, Pattnaik AK, Varadwaj PK. Stem cells: An overview with respect to cardiovascular and renal disease. *J Nat Sci Biol Med* 2010; **1**: 43-52 [PMID: 22096336 DOI: 10.4103/0976-9668.71674]

22 **Thomson JA**, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science* 1998; **282**: 1145-1147 [PMID: 9804556 DOI: 10.1126/science.282.5391.1145]

23 **Abad M**, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, Manzanares M, Ortega S, Serrano M. Reprogramming *in vivo* produces teratomas and iPS cells with totipotency features. *Nature* 2013; **502**: 340-345 [PMID: 24025773 DOI: 10.1038/nature12586]

24 **Volarevic V**, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and Safety Issues of Stem Cell-Based Therapy. *Int J Med Sci* 2018; **15**: 36-45 [PMID: 29333086 DOI: 10.7150/ijms.21666]

25 **Yu J**, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007; **318**: 1917-1920 [PMID: 18029452 DOI: 10.1126/science.1151526]

26 **Glicksman MA**. Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy. *Clin Ther* 2018; **40**: 1060-1065 [PMID: 30049501 DOI: 10.1016/j.clinthera.2018.06.004]

27 **Arjmand B**, Goodarzi P, Mohamadi-Jahani F, Falahzadeh K, Larijani B. Personalized Regenerative Medicine. *Acta Med Iran* 2017; **55**: 144-149 [PMID: 28282715]

28 **Brodehl A**, Ebbinghaus H, Deutsch MA, Gummert J, Gärtner A, Ratnavadivel S, Milting H. Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies. *Int J Mol Sci* 2019; **20** [PMID: 31489928 DOI: 10.3390/ijms20184381]

29 **Nagoshi N**, Okano H. Applications of induced pluripotent stem cell technologies in spinal cord injury. *J Neurochem* 2017; **141**: 848-860 [PMID: 28199003 DOI: 10.1111/jnc.13986]

30 **Yuasa S**, Fukuda K. Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era. *Expert Rev Cardiovasc Ther* 2008; **6**: 803-810 [PMID: 18570618 DOI: 10.1586/14779072.6.6.803]

31 **Chen IY**, Matsa E, Wu JC. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. *Nat Rev Cardiol* 2016; **13**: 333-349 [PMID: 27009425 DOI: 10.1038/nrcardio.2016.36]

32 **Galipeau J**, Sensébé L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. *Cell Stem Cell* 2018; **22**: 824-833 [PMID: 29859173 DOI: 10.1016/j.stem.2018.05.004]

33 **Evans MJ**, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981; **292**: 154-156 [PMID: 7242681 DOI: 10.1038/292154a0]

34 **Martin GR**. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 1981; **78**: 7634-7638 [PMID: 6950406 DOI: 10.1073/pnas.78.12.7634]

35 **Levenberg S**, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. *Proc Natl Acad Sci U S A* 2003; **100**: 12741-12746 [PMID: 14561891 DOI: 10.1073/pnas.1735463100]

36 **Solter D**, Knowles BB. Immunosurgery of mouse blastocyst. *Proc Natl Acad Sci U S A* 1975; **72**: 5099-5102 [PMID: 1108013 DOI: 10.1073/pnas.72.12.5099]

37 **Reubinoff BE**, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. *Nat Biotechnol* 2000; **18**: 399-404 [PMID: 10748519 DOI: 10.1038/74447]

38 **Mukherjee S**. Stem cell Characteristics and Applications. In: Singh R, Trivedi M. Biotechnology-Trends & Applications. Studium Press, LLC, USA, 2017: 277-299

39 **De Trizio E**, Brennan CS. The business of human embryonic stem cell research and an international analysis of relevant laws. *J Biolaw Bus* 2004; **7**: 14-22 [PMID: 15675095]

40 **Godfrey KJ**, Mathew B, Bulman JC, Shah O, Clement S, Gallicano GI. Stem cell-based treatments for Type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. *Diabet Med* 2012; **29**: 14-23 [PMID: 21883442 DOI: 10.1111/j.1464-5491.2011.03433.x]

41 **Stojkovic M**, Lako M, Stojkovic P, Stewart R, Przyborski S, Armstrong L, Evans J, Herbert M, Hyslop L, Ahmad S, Murdoch A, Strachan T. Derivation of human embryonic stem cells from day-8 blastocysts recovered after three-step *in vitro* culture. *Stem Cells* 2004; **22**: 790-797 [PMID: 15342943 DOI: 10.1634/stemcells.22-5-790]

42 **Stojkovic M**, Stojkovic P, Leary C, Hall VJ, Armstrong L, Herbert M, Nesbitt M, Lako M, Murdoch A. Derivation of a human blastocyst after heterologous nuclear transfer to donated oocytes. *Reprod Biomed Online* 2005; **11**: 226-231 [PMID: 16168222 DOI: 10.1016/s1472-6483(10)60962-5]

43 **Heng BC**, Tong GQ, Stojkovic M. The egg-sharing model for human therapeutic cloning research: managing donor selection criteria, the proportion of shared oocytes allocated to research, and amount of financial subsidy given to the donor. *Med Hypotheses* 2006; **66**: 1022-1024 [PMID: 16288969 DOI: 10.1016/j.mehy.2005.09.035]

44 **Kroon E**, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD, D'Amour KA, Carpenter MK, Baetge EE. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. *Nat Biotechnol* 2008; **26**: 443-452 [PMID: 18288110 DOI: 10.1038/nbt1393]

45 **Prokhorova TA**, Harkness LM, Frandsen U, Ditzel N, Schrøder HD, Burns JS, Kassem M. Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. *Stem Cells Dev* 2009; **18**: 47-54 [PMID: 18393673 DOI: 10.1089/scd.2007.0266]

46 **Ben-David U**, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. *Nat Rev Cancer* 2011; **11**: 268-277 [PMID: 21390058 DOI: 10.1038/nrc3034]

47 **Lee AS**, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nat Med* 2013; **19**: 998-1004 [PMID: 23921754 DOI: 10.1038/nm.3267]

48 **Laflamme MA**, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat Biotechnol* 2007; **25**: 1015-1024 [PMID: 17721512 DOI: 10.1038/nbt1327]

49 **Roy NS**, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. *Nat Med* 2006; **12**: 1259-1268 [PMID: 17057709 DOI: 10.1038/nm1495]

50 **Lee MO**, Moon SH, Jeong HC, Yi JY, Lee TH, Shim SH, Rhee YH, Lee SH, Oh SJ, Lee MY, Han MJ, Cho YS, Chung HM, Kim KS, Cha HJ. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. *Proc Natl Acad Sci U S A* 2013; **110**: E3281-E3290 [PMID: 23918355 DOI: 10.1073/pnas.1303669110]

51 **Kallas-Kivi A**, Trei A, Maimets T. Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells. *Stem Cells Int* 2016; **2016**: 1580701 [PMID: 27247576 DOI: 10.1155/2016/1580701]

52 **Wang H**, Gong P, Li J, Fu Y, Zhou Z, Liu L. Role of CD133 in human embryonic stem cell proliferation and teratoma formation. *Stem Cell Res Ther* 2020; **11**: 208 [PMID: 32460847 DOI: 10.1186/s13287-020-01729-0]

53 **Song WK**, Park KM, Kim HJ, Lee JH, Choi J, Chong SY, Shim SH, Del Priore LV, Lanza R. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. *Stem Cell Reports* 2015; **4**: 860-872 [PMID: 25937371 DOI: 10.1016/j.stemcr.2015.04.005]

54 **Alper J**. Geron gets green light for human trial of ES cell-derived product. *Nat Biotechnol* 2009; **27**: 213-214 [PMID: 19270655 DOI: 10.1038/nbt0309-213a]

55 **Schwartz SD**, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. *Lancet* 2015; **385**: 509-516 [PMID: 25458728 DOI: 10.1016/S0140-6736(14)61376-3]

56 **Schwartz SD**, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. *Lancet* 2012; **379**: 713-720 [PMID: 22281388 DOI: 10.1016/S0140-6736(12)60028-2]

57 **Liu Y**, Xu HW, Wang L, Li SY, Zhao CJ, Hao J, Li QY, Zhao TT, Wu W, Wang Y, Zhou Q, Qian C, Wang L, Yin ZQ. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. *Cell Discov* 2018; **4**: 50 [PMID: 30245845 DOI: 10.1038/s41421-018-0053-y]

58 **Vitillo L**, Durance C, Hewitt Z, Moore H, Smith A, Vallier L. GMP-grade neural progenitor derivation and differentiation from clinical-grade human embryonic stem cells. *Stem Cell Res Ther* 2020; **11**: 406 [PMID: 32948237 DOI: 10.1186/s13287-020-01915-0]

59 **Rezania A**, Bruin JE, Xu J, Narayan K, Fox JK, O'Neil JJ, Kieffer TJ. Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. *Stem Cells* 2013; **31**: 2432-2442 [PMID: 23897760 DOI: 10.1002/stem.1489]

60 **Menasché P**, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A, Cacciapuoti I, Al-Daccak R, Benhamouda N, Blons H, Agbulut O, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Charron D, Tartour E, Tachdjian G, Desnos M, Larghero J. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. *J Am Coll Cardiol* 2018; **71**: 429-438 [PMID: 29389360 DOI: 10.1016/j.jacc.2017.11.047]

61 **ViaCyte**. A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus. [accessed 2021 Jan 11]. In: ClinicalTrials.gov [Internet]. San Diego (CA): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02239354 ClinicalTrials.gov Identifier: NCT02239354

62 **Memon B**, Abdelalim EM. Stem Cell Therapy for Diabetes: Beta Cells *vs* Pancreatic Progenitors. *Cells* 2020; **9** [PMID: 31979403 DOI: 10.3390/cells9020283]

63 **Barker RA**, Parmar M, Studer L, Takahashi J. Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. *Cell Stem Cell* 2017; **21**: 569-573 [PMID: 29100010 DOI: 10.1016/j.stem.2017.09.014]

64 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

65 **Okita K**, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature* 2007; **448**: 313-317 [PMID: 17554338 DOI: 10.1038/nature05934]

66 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

67 **Yu J**, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 2009; **324**: 797-801 [PMID: 19325077 DOI: 10.1126/science.1172482]

68 **Loh YH**, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, Kim K, Miller JD, Ng K, Daley GQ. Generation of induced pluripotent stem cells from human blood. *Blood* 2009; **113**: 5476-5479 [PMID: 19299331 DOI: 10.1182/blood-2009-02-204800]

69 **Okita K**, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. *Philos Trans R Soc Lond B Biol Sci* 2011; **366**: 2198-2207 [PMID: 21727125 DOI: 10.1098/rstb.2011.0016]

70 **González F**, Boué S, Izpisúa Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming à la carte. *Nat Rev Genet* 2011; **12**: 231-242 [PMID: 21339765 DOI: 10.1038/nrg2937]

71 **Yamanaka S**. Induced pluripotent stem cells: past, present, and future. *Cell Stem Cell* 2012; **10**: 678-684 [PMID: 22704507 DOI: 10.1016/j.stem.2012.05.005]

72 **Warren L**, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 2010; **7**: 618-630 [PMID: 20888316 DOI: 10.1016/j.stem.2010.08.012]

73 **Yakubov E**, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. *Biochem Biophys Res Commun* 2010; **394**: 189-193 [PMID: 20188704 DOI: 10.1016/j.bbrc.2010.02.150]

74 **Anokye-Danso F**, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 2011; **8**: 376-388 [PMID: 21474102 DOI: 10.1016/j.stem.2011.03.001]

75 **Mochiduki Y**, Okita K. Methods for iPS cell generation for basic research and clinical applications. *Biotechnol J* 2012; **7**: 789-797 [PMID: 22378737 DOI: 10.1002/biot.201100356]

76 **Lee J**, Sayed N, Hunter A, Au KF, Wong WH, Mocarski ES, Pera RR, Yakubov E, Cooke JP. Activation of innate immunity is required for efficient nuclear reprogramming. *Cell* 2012; **151**: 547-558 [PMID: 23101625 DOI: 10.1016/j.cell.2012.09.034]

77 **Kim D**, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. *Cell Stem Cell* 2009; **4**: 472-476 [PMID: 19481515 DOI: 10.1016/j.stem.2009.05.005]

78 **Zhou H**, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 2009; **4**: 381-384 [PMID: 19398399 DOI: 10.1016/j.stem.2009.04.005]

79 **Liu X**, Chen J, Firas J, Paynter JM, Nefzger CM, Polo JM. Generation of Mouse-Induced Pluripotent Stem Cells by Lentiviral Transduction. *Methods Mol Biol* 2019; **1940**: 63-76 [PMID: 30788818 DOI: 10.1007/978-1-4939-9086-3\_5]

80 **Rhee YH**, Ko JY, Chang MY, Yi SH, Kim D, Kim CH, Shim JW, Jo AY, Kim BW, Lee H, Lee SH, Suh W, Park CH, Koh HC, Lee YS, Lanza R, Kim KS, Lee SH. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. *J Clin Invest* 2011; **121**: 2326-2335 [PMID: 21576821 DOI: 10.1172/JCI45794]

81 **Okano T**, Sawa Y, Barber E, Umezawa A. Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells and cell sheet technology: A report of the Symposium of Regenerative Medicine for Patients. *Regen Ther* 2015; **2**: 2-5 [PMID: 31245453 DOI: 10.1016/j.reth.2015.07.002]

82 **Hofrichter M**, Nimtz L, Tigges J, Kabiri Y, Schröter F, Royer-Pokora B, Hildebrandt B, Schmuck M, Epanchintsev A, Theiss S, Adjaye J, Egly JM, Krutmann J, Fritsche E. Comparative performance analysis of human iPSC-derived and primary neural progenitor cells (NPC) grown as neurospheres in vitro. *Stem Cell Res* 2017; **25**: 72-82 [PMID: 29112887 DOI: 10.1016/j.scr.2017.10.013]

83 **Generali M**, Casanova EA, Kehl D, Wanner D, Hoerstrup SP, Cinelli P, Weber B. Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells. *Acta Biomater* 2019; **97**: 333-343 [PMID: 31344511 DOI: 10.1016/j.actbio.2019.07.032]

84 **Sundberg M**, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells* 2013; **31**: 1548-1562 [PMID: 23666606 DOI: 10.1002/stem.1415]

85 **Pagliuca FW**, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. Generation of functional human pancreatic β cells in vitro. *Cell* 2014; **159**: 428-439 [PMID: 25303535 DOI: 10.1016/j.cell.2014.09.040]

86 **Wang Y**, Hu J, Jiao J, Liu Z, Zhou Z, Zhao C, Chang LJ, Chen YE, Ma PX, Yang B. Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds. *Biomaterials* 2014; **35**: 8960-8969 [PMID: 25085858 DOI: 10.1016/j.biomaterials.2014.07.011]

87 **Wimmer RA**, Leopoldi A, Aichinger M, Wick N, Hantusch B, Novatchkova M, Taubenschmid J, Hämmerle M, Esk C, Bagley JA, Lindenhofer D, Chen G, Boehm M, Agu CA, Yang F, Fu B, Zuber J, Knoblich JA, Kerjaschki D, Penninger JM. Human blood vessel organoids as a model of diabetic vasculopathy. *Nature* 2019; **565**: 505-510 [PMID: 30651639 DOI: 10.1038/s41586-018-0858-8]

88 **Takahashi J**. iPS cell-based therapy for Parkinson's disease: A Kyoto trial. *Regen Ther* 2020; **13**: 18-22 [PMID: 33490319 DOI: 10.1016/j.reth.2020.06.002]

89 **Schweitzer JS**, Song B, Herrington TM, Park TY, Lee N, Ko S, Jeon J, Cha Y, Kim K, Li Q, Henchcliffe C, Kaplitt M, Neff C, Rapalino O, Seo H, Lee IH, Kim J, Kim T, Petsko GA, Ritz J, Cohen BM, Kong SW, Leblanc P, Carter BS, Kim KS. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. *N Engl J Med* 2020; **382**: 1926-1932 [PMID: 32402162 DOI: 10.1056/NEJMoa1915872]

90 **Deinsberger J**, Reisinger D, Weber B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. *NPJ Regen Med* 2020; **5**: 15 [PMID: 32983575 DOI: 10.1038/s41536-020-00100-4]

91 **Yoshihara M**, Oguchi A, Murakawa Y. Genomic Instability of iPSCs and Challenges in Their Clinical Applications. *Adv Exp Med Biol* 2019; **1201**: 23-47 [PMID: 31898780 DOI: 10.1007/978-3-030-31206-0\_2]

92 **Mehat MS**, Sundaram V, Ripamonti C, Robson AG, Smith AJ, Borooah S, Robinson M, Rosenthal AN, Innes W, Weleber RG, Lee RWJ, Crossland M, Rubin GS, Dhillon B, Steel DHW, Anglade E, Lanza RP, Ali RR, Michaelides M, Bainbridge JWB. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration. *Ophthalmology* 2018; **125**: 1765-1775 [PMID: 29884405 DOI: 10.1016/j.ophtha.2018.04.037]

93 **Liu X**, Li W, Fu X, Xu Y. The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives. *Front Immunol* 2017; **8**: 645 [PMID: 28626459 DOI: 10.3389/fimmu.2017.00645]

94 **Hermsen J**, Brown ME. Humanized Mouse Models for Evaluation of PSC Immunogenicity. *Curr Protoc Stem Cell Biol* 2020; **54**: e113 [PMID: 32588980 DOI: 10.1002/cpsc.113]

95 **Azzolin L**, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M, Piccolo S. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. *Cell* 2014; **158**: 157-170 [PMID: 24976009 DOI: 10.1016/j.cell.2014.06.013]

96 **Nakajima-Koyama M**, Lee J, Ohta S, Yamamoto T, Nishida E. Induction of Pluripotency in Astrocytes through a Neural Stem Cell-like State. *J Biol Chem* 2015; **290**: 31173-31188 [PMID: 26553868 DOI: 10.1074/jbc.M115.683466]

97 **Panciera T**, Azzolin L, Fujimura A, Di Biagio D, Frasson C, Bresolin S, Soligo S, Basso G, Bicciato S, Rosato A, Cordenonsi M, Piccolo S. Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. *Cell Stem Cell* 2016; **19**: 725-737 [PMID: 27641305 DOI: 10.1016/j.stem.2016.08.009]

98 **Zanconato F**, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer. *Cancer Cell* 2016; **29**: 783-803 [PMID: 27300434 DOI: 10.1016/j.ccell.2016.05.005]

99 **Marcus AJ**, Woodbury D. Fetal stem cells from extra-embryonic tissues: do not discard. *J Cell Mol Med* 2008; **12**: 730-742 [PMID: 18194447 DOI: 10.1111/j.1582-4934.2008.00221.x]

100 **O'Donoghue K**, Fisk NM. Fetal stem cells. *Best Pract Res Clin Obstet Gynaecol* 2004; **18**: 853-875 [PMID: 15582543 DOI: 10.1016/j.bpobgyn.2004.06.010]

101 **Brunstein CG**, Wagner JE. Umbilical cord blood transplantation and banking. *Annu Rev Med* 2006; **57**: 403-417 [PMID: 16409157 DOI: 10.1146/annurev.med.57.051804.123642]

102 **Bauer G**, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. *Stem Cells Transl Med* 2018; **7**: 676-685 [PMID: 30063299 DOI: 10.1002/sctm.17-0282]

103 **Wu Z**, Zhang S, Zhou L, Cai J, Tan J, Gao X, Zeng Z, Li D. Thromboembolism Induced by Umbilical Cord Mesenchymal Stem Cell Infusion: A Report of Two Cases and Literature Review. *Transplant Proc* 2017; **49**: 1656-1658 [PMID: 28838459 DOI: 10.1016/j.transproceed.2017.03.078]

104 **Moll G**, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk HD, Geissler S, Reinke P. Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. *Trends Mol Med* 2019; **25**: 149-163 [PMID: 30711482 DOI: 10.1016/j.molmed.2018.12.006]

105 **Moll G**, Ignatowicz L, Catar R, Luecht C, Sadeghi B, Hamad O, Jungebluth P, Dragun D, Schmidtchen A, Ringdén O. Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. *Stem Cells Dev* 2015; **24**: 2269-2279 [PMID: 26192403 DOI: 10.1089/scd.2015.0120]

106 **Melmed GY**, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. *Inflamm Bowel Dis* 2015; **21**: 1809-1816 [PMID: 25985246 DOI: 10.1097/MIB.0000000000000441]

107 **Nakamura Y**, Miyaki S, Ishitobi H, Matsuyama S, Nakasa T, Kamei N, Akimoto T, Higashi Y, Ochi M. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. *FEBS Lett* 2015; **589**: 1257-1265 [PMID: 25862500 DOI: 10.1016/j.febslet.2015.03.031]

108 **Barriga F**, Ramírez P, Wietstruck A, Rojas N. Hematopoietic stem cell transplantation: clinical use and perspectives. *Biol Res* 2012; **45**: 307-316 [PMID: 23283440 DOI: 10.4067/S0716-97602012000300012]

109 **Petersdorf EW**. Optimal HLA matching in hematopoietic cell transplantation. *Curr Opin Immunol* 2008; **20**: 588-593 [PMID: 18674615 DOI: 10.1016/j.coi.2008.06.014]

110 **Ferrara JL**, Levine JE, Reddy P, Holler E. Graft-versus-host disease. *Lancet* 2009; **373**: 1550-1561 [PMID: 19282026 DOI: 10.1016/S0140-6736(09)60237-3]

111 **Dandoy CE**, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. *JAMA Netw Open* 2020; **3**: e1918668 [PMID: 31913492 DOI: 10.1001/jamanetworkopen.2019.18668]

112 **Cao W**, Guan L, Li X, Zhang R, Li L, Zhang S, Wang C, Xie X, Jiang Z, Wan D, Chi X. Clinical Analysis of Bloodstream Infections During Agranulocytosis After Allogeneic Hematopoietic Stem Cell Transplantation. *Infect Drug Resist* 2021; **14**: 185-192 [PMID: 33500639 DOI: 10.2147/IDR.S280869]

113 **Mohammadi Najafabadi M**, Soleimani M, Ahmadvand M, Soufi Zomorrod M, Mousavi SA. Treatment protocols for BK virus associated hemorrhagic cystitis after hematopoietic stem cell transplantation. *Am J Blood Res* 2020; **10**: 217-230 [PMID: 33224566]

114 **Hass R**, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 2011; **9**: 12 [PMID: 21569606 DOI: 10.1186/1478-811X-9-12]

115 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]

116 **Alt E**, Yan Y, Gehmert S, Song YH, Altman A, Gehmert S, Vykoukal D, Bai X. Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. *Biol Cell* 2011; **103**: 197-208 [PMID: 21332447 DOI: 10.1042/BC20100117]

117 **Lv FJ**, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. *Stem Cells* 2014; **32**: 1408-1419 [PMID: 24578244 DOI: 10.1002/stem.1681]

118 **Romito A**, Cobellis G. Pluripotent Stem Cells: Current Understanding and Future Directions. *Stem Cells Int* 2016; **2016**: 9451492 [PMID: 26798367 DOI: 10.1155/2016/9451492]

119 **Golchin A**, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. *Stem Cell Rev Rep* 2020; **16**: 427-433 [PMID: 32281052 DOI: 10.1007/s12015-020-09973-w]

120 **Squillaro T**, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update. *Cell Transplant* 2016; **25**: 829-848 [PMID: 26423725 DOI: 10.3727/096368915X689622]

121 **Vizoso FJ**, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. *Int J Mol Sci* 2017; **18** [PMID: 28841158 DOI: 10.3390/ijms18091852]

122 **Mushahary D**, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. *Cytometry A* 2018; **93**: 19-31 [PMID: 29072818 DOI: 10.1002/cyto.a.23242]

123 **Trohatou O**, Roubelakis MG. Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Past, Present, and Future. *Cell Reprogram* 2017; **19**: 217-224 [PMID: 28520465 DOI: 10.1089/cell.2016.0062]

124 **Galipeau J**. Mesenchymal Stromal Cells for Graft-versus-Host Disease: A Trilogy. *Biol Blood Marrow Transplant* 2020; **26**: e89-e91 [PMID: 32156632 DOI: 10.1016/j.bbmt.2020.02.023]

125 **Moroni L**, Fornasari PM. Human mesenchymal stem cells: a bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues. *J Cell Physiol* 2013; **228**: 680-687 [PMID: 22949310 DOI: 10.1002/jcp.24223]

126 **Dmitrieva RI**, Minullina IR, Bilibina AA, Tarasova OV, Anisimov SV, Zaritskey AY. Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities. *Cell Cycle* 2012; **11**: 377-383 [PMID: 22189711 DOI: 10.4161/cc.11.2.18858]

127 **Mohamed-Ahmed S**, Fristad I, Lie SA, Suliman S, Mustafa K, Vindenes H, Idris SB. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. *Stem Cell Res Ther* 2018; **9**: 168 [PMID: 29921311 DOI: 10.1186/s13287-018-0914-1]

128 **Iyyanki T**, Hubenak J, Liu J, Chang EI, Beahm EK, Zhang Q. Harvesting technique affects adipose-derived stem cell yield. *Aesthet Surg J* 2015; **35**: 467-476 [PMID: 25791999 DOI: 10.1093/asj/sju055]

129 **Huang SJ**, Fu RH, Shyu WC, Liu SP, Jong GP, Chiu YW, Wu HS, Tsou YA, Cheng CW, Lin SZ. Adipose-derived stem cells: isolation, characterization, and differentiation potential. *Cell Transplant* 2013; **22**: 701-709 [PMID: 23068312 DOI: 10.3727/096368912X655127]

130 **Lindroos B**, Suuronen R, Miettinen S. The potential of adipose stem cells in regenerative medicine. *Stem Cell Rev Rep* 2011; **7**: 269-291 [PMID: 20853072 DOI: 10.1007/s12015-010-9193-7]

131 **Tobita M**, Orbay H, Mizuno H. Adipose-derived stem cells: current findings and future perspectives. *Discov Med* 2011; **11**: 160-170 [PMID: 21356171]

132 **Nombela-Arrieta C**, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. *Nat Rev Mol Cell Biol* 2011; **12**: 126-131 [PMID: 21253000 DOI: 10.1038/nrm3049]

133 **Pittenger MF**, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. *NPJ Regen Med* 2019; **4**: 22 [PMID: 31815001 DOI: 10.1038/s41536-019-0083-6]

134 **Ren G**, Rezaee M, Razavi M, Taysir A, Wang J, Thakor AS. Adipose tissue-derived mesenchymal stem cells rescue the function of islets transplanted in sub-therapeutic numbers *via* their angiogenic properties. *Cell Tissue Res* 2019; **376**: 353-364 [PMID: 30707291 DOI: 10.1007/s00441-019-02997-w]

135 **Le Blanc K**, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 2004; **363**: 1439-1441 [PMID: 15121408 DOI: 10.1016/S0140-6736(04)16104-7]

136 **Moll G**, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. *Front Immunol* 2020; **11**: 1091 [PMID: 32574263 DOI: 10.3389/fimmu.2020.01091]

137 **Wu X**, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. *Stem Cell Res Ther* 2020; **11**: 345 [PMID: 32771052 DOI: 10.1186/s13287-020-01855-9]

138 **Kabat M**, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? *Stem Cells Transl Med* 2020; **9**: 17-27 [PMID: 31804767 DOI: 10.1002/sctm.19-0202]

139 **Kurtzberg J**, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D; MSB-GVHD001/002 Study Group. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. *Biol Blood Marrow Transplant* 2020; **26**: 845-854 [PMID: 32018062 DOI: 10.1016/j.bbmt.2020.01.018]

140 **Kurtzberg J**, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, Satwani P, Teira P, Hayes J, Burke E; MSB-275 Study Group. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. *Biol Blood Marrow Transplant* 2020; **26**: 855-864 [PMID: 32044400 DOI: 10.1016/j.bbmt.2020.01.026]

141 **Kebriaei P**, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ. A Phase 3 Randomized Study of Remestemcel-L *vs* Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. *Biol Blood Marrow Transplant* 2020; **26**: 835-844 [PMID: 31505228 DOI: 10.1016/j.bbmt.2019.08.029]

142 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016; **388**: 1281-1290 [PMID: 27477896 DOI: 10.1016/S0140-6736(16)31203-X]

143 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. *Gastroenterology* 2018; **154**: 1334-1342.e4 [PMID: 29277560 DOI: 10.1053/j.gastro.2017.12.020]

144 **Karantalis V**, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. *Circ Res* 2015; **116**: 1413-1430 [PMID: 25858066 DOI: 10.1161/CIRCRESAHA.116.303614]

145 **Bartunek J**, Davison B, Sherman W, Povsic T, Henry TD, Gersh B, Metra M, Filippatos G, Hajjar R, Behfar A, Homsy C, Cotter G, Wijns W, Tendera M, Terzic A. Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. *Eur J Heart Fail* 2016; **18**: 160-168 [PMID: 26662998 DOI: 10.1002/ejhf.434]

146 **Teerlink JR**, Metra M, Filippatos GS, Davison BA, Bartunek J, Terzic A, Gersh BJ, Povsic TJ, Henry TD, Alexandre B, Homsy C, Edwards C, Seron A, Wijns W, Cotter G; CHART Investigators. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. *Eur J Heart Fail* 2017; **19**: 1520-1529 [PMID: 28560782 DOI: 10.1002/ejhf.898]

147 **Wang D**, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS, Silver RM, Chen W, Shi S, Sun L. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. *Cell Transplant* 2013; **22**: 2267-2277 [PMID: 24388428 DOI: 10.3727/096368911X582769c]

148 **Wang D**, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. *Stem Cell Reports* 2018; **10**: 933-941 [PMID: 29478901 DOI: 10.1016/j.stemcr.2018.01.029]

149 **Cai J**, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. *Diabetes Care* 2016; **39**: 149-157 [PMID: 26628416 DOI: 10.2337/dc15-0171]

150 **Fričová D**, Korchak JA, Zubair AC. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease. *NPJ Regen Med* 2020; **5**: 20 [PMID: 33298940 DOI: 10.1038/s41536-020-00106-y]

151 **Liu XY**, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. *World J Stem Cells* 2020; **12**: 787-802 [PMID: 32952859 DOI: 10.4252/wjsc.v12.i8.787]

152 **Cell Trials Data**. The Role of MSC to Treat Coronavirus Pneumonia and ARDS. Part 1: Is the Emperor Wearing Clothes? [cited 20 Jan 2021]. In: Cell Trials Data [Internet]. Available online at: https://celltrials.org/news/role-msc-treat-coronavirus-pneumoniaand-ards-part-1-is-emperor-wearing-clothes

153 **Kumar R**, Sharma A, Siddiqui MH, Tiwari RK. Prediction of Metabolism of Drugs using Artificial Intelligence: How far have we reached? *Curr Drug Metab* 2016; **17**: 129-141 [PMID: 26526829 DOI: 10.2174/1389200216666151103121352]

154 **Kumar R**, Sharma A, Siddiqui MH, Tiwari RK. Prediction of Human Intestinal Absorption of Compounds Using Artificial Intelligence Techniques. *Curr Drug Discov Technol* 2017; **14**: 244-254 [PMID: 28382857 DOI: 10.2174/1570163814666170404160911]

155 **Kumar R**, Sharma A, Siddiqui MH, Tiwari RK. Promises of Machine Learning Approaches in Prediction of Absorption of Compounds. *Mini Rev Med Chem* 2018; **18**: 196-207 [PMID: 28302041 DOI: 10.2174/1389557517666170315150116]

156 **Haenlein M**, Kaplan A. A brief history of artificial intelligence: On the past, present, and future of artificial intelligence. *Calif Manage Rev* 2019; **61**: 5-14 [DOI: 10.1177/0008125619864925]

157 **Wang L**, Zhang HC, Wang Q. On the concepts of artificial intelligence and innovative design in product design. *IOP Conf Ser Mater Sci Eng* 2019; **573**: 12095 [DOI: 10.1088/1757-899X/573/1/012095]

158 **Kumar R**, Sharma A, Varadwaj P, Ahmad A, Ashraf GM. Classification of oral bioavailability of drugs by machine learning approaches: a comparative study. *J Comp Int Sci* 2011; **2**: 1-18 [DOI: 10.6062/JCIS.2011.02.03.0045]

159 **He J**, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. *Nat Med* 2019; **25**: 30-36 [PMID: 30617336 DOI: 10.1038/s41591-018-0307-0]

160 **Kumar R**, Sharma A, Siddiqui MH, Tiwari RK. Prediction of Drug-Plasma Protein Binding Using Artificial Intelligence Based Algorithms. *Comb Chem High Throughput Screen* 2018; **21**: 57-64 [PMID: 29256344 DOI: 10.2174/1386207321666171218121557]

161 **Sharma A**, Kumar R, Ranjta S, Varadwaj PK. SMILES to Smell: Decoding the Structure-Odor Relationship of Chemical Compounds Using the Deep Neural Network Approach. *J Chem Inf Model* 2021; **61**: 676-688 [PMID: 33449694 DOI: 10.1021/acs.jcim.0c01288]

162 **Jiang F**, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in healthcare: past, present and future. *Stroke Vasc Neurol* 2017; **2**: 230-243 [PMID: 29507784 DOI: 10.1136/svn-2017-000101]

163 **Buch VH**, Ahmed I, Maruthappu M. Artificial intelligence in medicine: current trends and future possibilities. *Br J Gen Pract* 2018; **68**: 143-144 [PMID: 29472224 DOI: 10.3399/bjgp18X695213]

164 **Salehnasab C**, Hajifathali A, Asadi F, Roshandel E, Kazemi A, Roshanpoor A. Machine Learning Classification Algorithms to Predict aGvHD following Allo-HSCT: A Systematic Review. *Methods Inf Med* 2019; **58**: 205-212 [PMID: 32349154 DOI: 10.1055/s-0040-1709150]

165 **Radakovich N**, Nagy M, Nazha A. Artificial Intelligence in Hematology: Current Challenges and Opportunities. *Curr Hematol Malig Rep* 2020; **15**: 203-210 [PMID: 32239350 DOI: 10.1007/s11899-020-00575-4]

166 **Saba L**, Biswas M, Kuppili V, Cuadrado Godia E, Suri HS, Edla DR, Omerzu T, Laird JR, Khanna NN, Mavrogeni S, Protogerou A, Sfikakis PP, Viswanathan V, Kitas GD, Nicolaides A, Gupta A, Suri JS. The present and future of deep learning in radiology. *Eur J Radiol* 2019; **114**: 14-24 [PMID: 31005165 DOI: 10.1016/j.ejrad.2019.02.038]

167 **Kusumoto D**, Yuasa S. The application of convolutional neural network to stem cell biology. *Inflamm Regen* 2019; **39**: 14 [PMID: 31312276 DOI: 10.1186/s41232-019-0103-3]

168 **Joutsijoki H**, Haponen M, Rasku J, Aalto-Setälä K, Juhola M. Machine Learning Approach to Automated Quality Identification of Human Induced Pluripotent Stem Cell Colony Images. *Comput Math Methods Med* 2016; **2016**: 3091039 [PMID: 27493680 DOI: 10.1155/2016/3091039]

169 **Kavitha MS**, Kurita T, Ahn BC. Critical texture pattern feature assessment for characterizing colonies of induced pluripotent stem cells through machine learning techniques. *Comput Biol Med* 2018; **94**: 55-64 [PMID: 29407998 DOI: 10.1016/j.compbiomed.2018.01.005]

170 **Kavitha MS**, Kurita T, Park SY, Chien SI, Bae JS, Ahn BC. Deep vector-based convolutional neural network approach for automatic recognition of colonies of induced pluripotent stem cells. *PLoS One* 2017; **12**: e0189974 [PMID: 29281701 DOI: 10.1371/journal.pone.0189974]

171 **Kusumoto D**, Lachmann M, Kunihiro T, Yuasa S, Kishino Y, Kimura M, Katsuki T, Itoh S, Seki T, Fukuda K. Automated Deep Learning-Based System to Identify Endothelial Cells Derived from Induced Pluripotent Stem Cells. *Stem Cell Reports* 2018; **10**: 1687-1695 [PMID: 29754958 DOI: 10.1016/j.stemcr.2018.04.007]

172 **Waisman A**, La Greca A, Möbbs AM, Scarafía MA, Santín Velazque NL, Neiman G, Moro LN, Luzzani C, Sevlever GE, Guberman AS, Miriuka SG. Deep Learning Neural Networks Highly Predict Very Early Onset of Pluripotent Stem Cell Differentiation. *Stem Cell Reports* 2019; **12**: 845-859 [PMID: 30880077 DOI: 10.1016/j.stemcr.2019.02.004]

173 **Juhola M**, Penttinen K, Joutsijoki H, Aalto-Setälä K. Analysis of Drug Effects on iPSC Cardiomyocytes with Machine Learning. *Ann Biomed Eng* 2021; **49**: 129-138 [PMID: 32367466 DOI: 10.1007/s10439-020-02521-0]

174 **Juhola M**, Penttinen K, Joutsijoki H, Varpa K, Saarikoski J, Rasku J, Siirtola H, Iltanen K, Laurikkala J, Hyyrö H, Hyttinen J, Aalto-Setälä K. Signal analysis and classification methods for the calcium transient data of stem cell-derived cardiomyocytes. *Comput Biol Med* 2015; **61**: 1-7 [PMID: 25841082 DOI: 10.1016/j.compbiomed.2015.03.016]

175 **Hwang H**, Liu R, Maxwell JT, Yang J, Xu C. Machine learning identifies abnormal Ca2+ transients in human induced pluripotent stem cell-derived cardiomyocytes. *Sci Rep* 2020; **10**: 16977 [PMID: 33046816 DOI: 10.1038/s41598-020-73801-x]

176 **Nishino K**, Takasawa K, Okamura K, Arai Y, Sekiya A, Akutsu H, Umezawa A. Identification of an epigenetic signature in human induced pluripotent stem cells using a linear machine learning model. *Hum Cell* 2021; **34**: 99-110 [PMID: 33047283 DOI: 10.1007/s13577-020-00446-3]

177 **Liu YYF**, Lu Y, Oh S, Conduit GJ. Machine learning to predict mesenchymal stem cell efficacy for cartilage repair. *PLoS Comput Biol* 2020; **16**: e1008275 [PMID: 33027251 DOI: 10.1371/journal.pcbi.1008275]

178 **Lee LX**, Li SC. Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective. *World J Stem Cells* 2020; **12**: 706-720 [PMID: 32952853 DOI: 10.4252/wjsc.v12.i8.706]

179 **Ng AP**, Alexander WS. Haematopoietic stem cells: past, present and future. *Cell Death Discov* 2017; **3**: 17002 [PMID: 28180000 DOI: 10.1038/cddiscovery.2017.2]

180 **Sniecinski I**, Seghatchian J. Artificial intelligence: A joint narrative on potential use in pediatric stem and immune cell therapies and regenerative medicine. *Transfus Apher Sci* 2018; **57**: 422-424 [PMID: 29784537 DOI: 10.1016/j.transci.2018.05.004]

181 **Polak DJ**. Regenerative medicine. Opportunities and challenges: a brief overview. *J R Soc Interface* 2010; **7 Suppl 6**: S777-S781 [PMID: 20826477 DOI: 10.1098/rsif.2010.0362.focus]

182 **Durant F**, Lobo D, Hammelman J, Levin M. Physiological controls of large-scale patterning in planarian regeneration: a molecular and computational perspective on growth and form. *Regeneration (Oxf)* 2016; **3**: 78-102 [PMID: 27499881 DOI: 10.1002/reg2.54]

183 **Roost MS**, van Iperen L, Ariyurek Y, Buermans HP, Arindrarto W, Devalla HD, Passier R, Mummery CL, Carlotti F, de Koning EJ, van Zwet EW, Goeman JJ, Chuva de Sousa Lopes SM. KeyGenes, a Tool to Probe Tissue Differentiation Using a Human Fetal Transcriptional Atlas. *Stem Cell Reports* 2015; **4**: 1112-1124 [PMID: 26028532 DOI: 10.1016/j.stemcr.2015.05.002]

184 **Morris SA**, Cahan P, Li H, Zhao AM, San Roman AK, Shivdasani RA, Collins JJ, Daley GQ. Dissecting engineered cell types and enhancing cell fate conversion *via* CellNet. *Cell* 2014; **158**: 889-902 [PMID: 25126792 DOI: 10.1016/j.cell.2014.07.021]

185 **Shamblott MJ**, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, Huggins GR, Gearhart JD. Derivation of pluripotent stem cells from cultured human primordial germ cells. *Proc Natl Acad Sci U S A* 1998; **95**: 13726-13731 [PMID: 9811868 DOI: 10.1073/pnas.95.23.13726]

186 **Lorenz E**, Uphoff D, Reid Tr, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. *J Natl Cancer Inst* 1951; **12**: 197-201 [PMID: 14874130]

187 **Thomas ED**, Storb R, Fefer A, Slichter SJ, Bryant JI, Buckner CD, Neiman PE, Clift RA, Funk DD, Lerner KE. Aplastic anaemia treated by marrow transplantation. *Lancet* 1972; **1**: 284-289 [PMID: 4109931 DOI: 10.1016/s0140-6736(72)90292-9]

188 **Baron JH**. Evolution of clinical research: A history before and beyond James Lind. *Perspect Clin Res* 2012; **3**: 149 [PMID: 23293765 DOI: 10.4103/2229-3485.103599]

**Footnotes**

**Conflict-of-interest statement:** Authors have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 16, 2021

**First decision:** March 17, 2021

**Article in press:** May 20, 2021

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cao HC **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:** Xing YX

**Figure Legends**



**Figure 1 Current strategies and approaches in regenerative medicine.** A: Strategies in regenerative medicines; B: Mesenchymal cell differentiation; C: Non-integrating reprogramming to make induced pluripotent stem cells (iPSCs); D: Artificial intelligence algorithms to assist iPSC identification.



**Figure 2 Characteristics and therapeutic potential of mesenchymal stem cells.** Sources of mesenchymal stem cells (MSCs) are shown as adipose tissue, umbilical cord, and bone marrow. MSCs are characterized by positive and negative markers and may be differentiated for clinical applications. The immunomodulatory properties of MSCs make them a promising candidate for cell-based therapies. NK cell: Natural killer cell.



**Figure 3 Commonly used machine learning and deep learning algorithms.**

****

**Figure 4 General schema for artificial intelligence-based prediction models development.** CNN: Convolutional neural network.

**Table 1 Summary of the clinical applications of different types of stem cells**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Type of stem cell** | **Discovery time** | **Source** | **Advantages** | **Disadvantages** | **Clinical applications and prospects** |
| Embryonic stem cells | mESC was first derived in 1980 by Evans and Kaufman[33] in the United Kingdom and Martin[34] in the United States. hESC was derived by Thomson *et al*[22] isolated from preimplantation blastocysts in 1998 | ICM of embryo | Maximum potency and these cells have the potential to differentiate into any cell type of the body | Ethical concerns, risk of developing teratomas and tumors when these undifferentiated cells are implanted *in vivo*[44-47] | Spinal cord injury[54], macular degeneration[55-58], diabetes mellitus[59], ischemic heart disease[60] |
| Induced pluripotent stem cells | Induced pluripotent stem cells were first successfully generated by Takahashi and Yamanaka[64] in 2006 | Fibroblast cells | These cells have the potential to differentiate into any cell type of the body. Overcomes the ethical concerns associated with embryonic stem cell research and clinical use. Organoid formation, and scope for personalized therapies | Genomic instability, carcinogenicity, immunological rejection | Macular degeneration[81] and Parkinson's disease[89] |
| Fetal stem cells | First isolated and cultured by John Gearhart and his team at the Johns Hopkins University School of Medicine in 1998[185] | Umbilical cord blood cells | High availability and reduced ethical concerns. Higher expansion rate. Possess osteogenic differentiation capabilities. Produce 2.5-fold more insulin than bone marrow derived cells | May not have adipogenic potential | Pancreatic islet cell generation *in vitro*. GvHD and systemic lupus erythematosus |
| Amniotic fluid and placenta | Harvested with minimal invasiveness | No clinical trials have yet been conducted to assess the safety and effectiveness of these stem cells | Potential treatment for nerve injuries or neuronal degenerative diseases. Bladder regeneration, kidney, lung, heart, heart valve, diaphragm, bone, cartilage and blood vessel formation. Treatment for skin and ocular diseases, inflammatory bowel disease, lung injuries, cartilage defects, Duchenne muscular dystrophy, and stroke. Also used in peripheral nerve regeneration |
| **Adult stem cells** |
| Hematopoietic stem cells | First discovered for clinical use in mice in 1950’s and for clinical use in human in 1970[186,187] | Bone marrow | Multipotent cells | Risks of GvHD[110]. Risks of bloodstream infections caused by Gram-negative bacteria associated with allogeneic hematopoietic transplantation[111,112]. Hemorrhagic cystitis is another complication that has been reported in patients post hematopoietic stem cell transplantation[113] | Hematopoietic stem cell transplantation is used as therapy for several malignant and non-malignant disorders and autoimmune diseases. These cells are also used for the recovery of patients undergoing chemotherapy and radiotherapy[108] |
| Mesenchymal stem cells | First derived in 1970 and first report of clinical use in 2004[188] | Bone marrow | Potential to differentiate osteocytes, chondrocytes, adipocyte. Multipotentiality, immunomodulatory, anti-inflammatory, efficient homing capacity to injured sites, and minimum ethical issues[121-123] | Procurement of cells from this source is often painful and carries the risk of infection. Cell yield and differentiation potential is dependent on donor characteristics | Generation of pancreatic cells *in vitro*. Orthopedic conditions characterized by large bone defects, including articular cartilage repair and osteoarthritis, rheumatoid arthritis. BM-MSCs may also be used to treat non-unions, osteonecrosis of the femoral head and to promote growth in osteogenesis imperfecta. Potentially promising treatment for myocardial infarction, GvHD, systemic lupus erythematosus and multiple sclerosis |
|  | First derived in 2001[185] | Adipose tissue isolated from liposuction, lipoplasty or lipectomy materials | This source results in the isolation of up to 500 times more stem cells than BM (5 × 103 cells from 1 g of AT). AT is accessible and abundant and secretes several angiogenic and antiapoptotic cytokines. The immunosuppressive effects of AT-MSCs are stronger than those of BM-MSCs | Cells from this source have inferior osteogenic and chondrogenic potential in comparison to BM-MSCs | Immunosuppressive GvHD therapy. Potential for cell-based therapy for radiculopathy, myocardial infarction, and neuropathic pain. Cosmetic/dermatological applications. Successfully used in the treatment of skeletal muscle-injuries, meniscus damage and tendon, rotator cuff and peripheral nerve regeneration |

AT: Adipose tissue; AT-MSCs: Adipose-tissue derived mesenchymal stem cells; BM-MSCs: Bone marrow derived mesenchymal stem cells; GvDH: Graft *vs* host disease; hESC: Human embryonic stem cell; ICM: Inner cell mass; mESC: Mouse embryonic stem cell.

**Table 2 Status of mesenchymal cell-based therapies for different diseases**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Disease category** | **Target disease** | **Clinical trial phase** | **Cell source** | **Company** | **Product name** | **ID No.** | **Status** |
|  GvHD | GvHD | Phase III | Mesenchymal stem cells (allogenic bone marrow derived) | Osiris Therapeutics | Prochymal | NCT00366145 | Approved *via* Notice of Compliance with conditions (NOC/c)[32] |
|  | Pediatric (GvHD, Grade III and IV) | Phase III | Mesenchymal stem cells (allogenic bone marrow derived) | Mesoblast | Remestemcel-L (Ryoncil™) | NCT02336230 | Prescription Drug User Fee Act (PDUFA) set by US FDA action and Remestemcel-L will be commercially available in the United States (if approved)[124,139-141] |
| Crohn’s disease |  | Phase III | Autologous AT-MSC | Cellerix | - | NCT00475410 | Completed in 2009 but failed |
|  |  | Phase III | Allogenic, AT-MSC | TiGenix | Alofisel® | NCT01541579 | Approved in 2018, by the European Medicines Agency[142, 143] |
| Cardiovascular diseases | Chronic advanced ischemic heart failure | Phase III | Autologous BM-MSC | - | - | NCT01768702 | Beneficial but not approved yet, further studies need to be undertaken[144-146] |
| Autoimmune diseases | Systemic lupus erythematosus | Phase I/II | Allogenic BM-MSC, UC-MSC | - | - | NCT01741857, NCT00698191 | Ongoing[147,148] |
|  | Type I diabetes | Phase I/II | Allogenic, UC-MSC combined with aulogous BM-MSC | - | - | NCT01374854 | Ongoing[149] |
| Neurodegenerative diseases | Parkinson’s disease | Phase I/II | Allogenic BM-MSC | - | - | NCT02611167 | Completed but more interventional studies underway[150] |
|  | Alzheimer’s disease | Phase I | Allogenic UC MSC, Longeveron MSC, BM MSC | - | - | NCT04040348, NCT02600130, NCT02600130 | Ongoing[151] |
| SARS-CoV-2 | COVID-19 | Phase II/III | BM-MSC, AT-MSC, Placenta derived MSC | Mesoblast, Athersys; Tigenix/Takeda; Pluristem | MultiStem; SPECELL |  | Ongoing[136,152] |

AT-MSC: Adipose-tissue derived mesenchymal stem cells; BM-MSC: Bone marrow derived mesenchymal stem cells; COVID19: Coronavirus-induced disease 2019; SARSCoV-2: Severe acute respiratory distress syndrome coronavirus-2; UC-MSC: Umbilical cord derived mesenchymal stem cells.

**Table 3 Summary of recent artificial intelligence-based stem cells therapies**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study objectives** | **Applied AI algorithm** | **Important conclusions** | **Study group** |
| iPSC-derived endothelial cells Identification without the application of molecular labelling using CNN | CNN | Prediction accuracy was a function of pixel size of the images and network depth. The k-fold cross validation suggested that morphological features alone could be enough for optimizing CNNs and they can deliver a high value prediction | Kusumoto and Yuasa[167] (2019) |
| Automated identification of the iPSC colony images quality | SVM, k-NN | k-NN yielded 62% of the accuracy which was found to be better than the previous studies of that time | Joutsijoki *et al*[168] (2016) |
| Assess automated texture descriptors of segmented colony regions of iPSCs and to check their potential | SVM, RF, MLP, Adaboost, DT | SVM, RF and Adaboost classifiers were concluded to exhibit superior classification ability than MLP and DT | Kavitha *et al*[169] (2018) |
| Develop a V-CNN model to distinguish the colony-characteristics on the basis of extracted descriptors of the iPSC colony | CNN | Recall, precision, and F-measure values by CNN were found to be comparatively much higher than the SVM. Colony quality accuracy was found to be 95.5% (morphological), 91.0% (textural) and 93.2% (textural) | Kavitha *et al*[170] (2017) |
| Use CNNs with transmitted light microscopy images to find out pluripotent stem cells from initial differentiating cells | CNN | CNN can be trained to distinguish among differentiated and undifferentiated cells with an accuracy of 99% | Waisman *et al*[172] (2019) |
| Use machine learning algorithms to analyze drug effects on iPSC cardiomyocytes | NB, KNN, LS-SVM, DT, multinomial logistic regression | Classification accuracy of the algorithm developed was found to be nearly 79% | Juhola *et al*[173] (2021) |
| To build an analytical procedure for automatic evaluation of Ca2+ transient abnormality, by applying SVM together with an analytical algorithm | SVM | The training and test accuracies were found to be 88% and 87% respectively | Hwang *et al*[175] (2020) |
| To develop a linear classification-learning model to differentiate among somatic cells, iPSCs, ESCs, and ECCs on the basis of their DNA methylation profiles | Jubatus (ML analytical platform) | The accuracy of the ML model in identifying various cell types was found to be 94.23%. Also, component analysis of the learned models identified the distinct epigenetic signatures of the iPSCs | Nishino *et al*[176] (2021) |

AI: Artificial intelligence; CNN: Convolution neural network; DT: Decision tree; ECCs: Embryonal carcinoma cells; ESCs: Embryonic stem cells; iPSC: Induced pluripotent stem cells; k-NN: K-nearest neighbor; LS-SVM: Least-squares support-vector machines; MLP: Multilayer perceptron; RF: Random forest; SVM: Support vector machine.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**